NEPG(SZ:000597) Zheng Quan Zhi Xing·2025-06-10 12:47Core Viewpoint - The legal opinion from Beijing Deheng Law Firm confirms that Jiangxi Fangda Steel Group Co., Ltd., an action-in-concert party of the controlling shareholder, plans to increase its stake in Northeast Pharmaceutical Group Co., Ltd. This move is based on confidence in the company's future development and aims to enhance its market value [2][4]. Group 1: Shareholder Information - The increasing party, Fangda Steel, was established in May 1959 with a registered capital of 1,035.339 million RMB and operates in various sectors including steel production and trade [4][5]. - Fangda Steel has confirmed that it does not fall under any prohibitive conditions for acquiring shares as per the relevant regulations [5][6]. Group 2: Details of the Increase - The planned increase in shares is between 75 million RMB and 150 million RMB [6]. - The increase will be executed through the Shenzhen Stock Exchange within six months starting from December 11, 2024, and will be based on market conditions [6][7]. - The funding for this increase will come from Fangda Steel's own funds and special loans [6][7]. Group 3: Compliance and Disclosure - The increase is structured to comply with the regulations, including a commitment not to sell shares for six months post-increase [7][9]. - The controlling shareholders and their concerted actions will not change as a result of this increase, thus not affecting the company's listing status [8][9]. - The company has fulfilled its current disclosure obligations regarding this increase [9].